title: Application of molecular modeling to analysis of inhibition of kinesin motor proteins of the BimC subfamily by monastrol and related compounds.
abstract: Application of molecular modeling approaches has potential to contribute to rational drug design. These approaches may be especially useful when attempting to elucidate the structural features associated with novel drug targets. In this study, molecular docking and molecular dynamics were applied to studies of inhibition of the human motor protein denoted HsEg5 and other homologues in the BimC subfamily. These proteins are essential for mitosis, so compounds that inhibit their activity may have potential as anticancer therapeutics. The discovery of a small-molecule cell-permeable inhibitor, monastrol, has stimulated research in this area. Interestingly, monastrol is reported to inhibit the human and Xenopus forms of Eg5, but not those from Drosophila and Aspergillus. In this study, homology modeling was used to generate models of the Xenopus, Drosophila, and Aspergillus homologues, using the crystal structure of the human protein in complex with monastrol as a template. A series of known inhibitors was docked into each of the homologues, and the differences in binding energies were consistent with reported experimental data. Molecular dynamics revealed significant changes in the structure of the Aspergillus homologue that may contribute to its relative insensitivity to monastrol and related compounds.
authors.affiliation: Department of Biochemistry, Virginia Polytechnic Institute and State University, 201 Engel Hall, Blacksburg, Virginia 24061, USA. drbevan@vt.edu
authors.forename: David R
authors.initials: DR
authors.lastname: Bevan
authors.forename: James F
authors.initials: JF
authors.lastname: Garst
authors.forename: Caroline K
authors.initials: CK
authors.lastname: Osborne
authors.forename: Angela M
authors.initials: AM
authors.lastname: Sims
mesh_terms: D000818:Animals; D029721:Drosophila Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D005656:Fungal Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D016547:Kinesins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D008958:Models, Molecular; D020409:Molecular Motor Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D011485:Protein Binding / Q000502:physiology; D017433:Protein Structure, Secondary / Q000502:physiology; D011743:Pyrimidines / Q000378:metabolism* / Q000494:pharmacology; D013871:Thiones / Q000378:metabolism* / Q000494:pharmacology; D029867:Xenopus Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism
chemical_list: C094560:BimC protein, Aspergillus nidulans; D029721:Drosophila Proteins; D005656:Fungal Proteins; D020409:Molecular Motor Proteins; D011743:Pyrimidines; D013871:Thiones; D029867:Xenopus Proteins; C400223:monastrol; D016547:Kinesins